A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

@article{Rosenberg2013API,
  title={A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma},
  author={Jonathan E Rosenberg and Richard Martin Bambury and Eliezer M. Van Allen and Harry A. Drabkin and Primo N. Lara and Andrea Lynne Harzstark and Nikhil Wagle and Robert Alan Figlin and Gregory W. Smith and Levi A. Garraway and Toni K Choueiri and Fredrik Erlandsson and Damian A. Laber},
  journal={Investigational New Drugs},
  year={2013},
  volume={32},
  pages={178-187}
}
Background DNA aptamers represent a novel strategy in anti-cancer medicine. AS1411, a DNA aptamer targeting nucleolin (a protein which is overexpressed in many tumor types), was evaluated in patients with metastatic, clear-cell, renal cell carcinoma (RCC) who had failed treatment with ≥1 prior tyrosine kinase inhibitor. Methods In this phase II, single-arm study, AS1411 was administered at 40 mg/kg/day by continuous intravenous infusion on days 1–4 of a 28-day cycle, for two cycles. Primary… CONTINUE READING
44 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Cancer statistics , 2012

  • RJ Motzer, TE Hutson, P Tomczak
  • 2012

Is oncology ready for 1000 rare diseases? InMedscape oncology

  • D Kerr
  • www.medscape.com. Accessed June 2012 Invest New…
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…